Baylor College of Medicine: Study - Cholesterol Substantially Reduced With Oral PCSK9 Inhibitor
March 07, 2023
March 07, 2023
HOUSTON, Texas, March 7 (TNSjou) -- The Baylor College of Medicine issued the following news:
A new study led by Baylor College of Medicine and presented at the American College of Cardiology's Annual Scientific Session together with World Congress of Cardiology found that an oral PCSK9 inhibitor called MK-0616 reduced LDL, or "bad," cholesterol by more than 60%.
MK-0616, an experimental oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, sub . . .
A new study led by Baylor College of Medicine and presented at the American College of Cardiology's Annual Scientific Session together with World Congress of Cardiology found that an oral PCSK9 inhibitor called MK-0616 reduced LDL, or "bad," cholesterol by more than 60%.
MK-0616, an experimental oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, sub . . .